Sugi Predict

Sugi Predict / Compounds / SCHEMBL13978024

SCHEMBL13978024

SCHEMBL13978024

NCc1ccc(-c2nnc(-c3ncccn3)nn2)cc1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 2/20 0.78
▸ HRH3 Q9Y5N1 1/20 0.48
▸ TAAR1 Q96RJ0 4/20 0.47
▸ LOXL2 Q9Y4K0 4/20 0.46
▸ CYP2A6 P11509 1/20 0.46
▸ LTA4H P09960 1/20 0.40
▸ NPC1 O15118 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ AKT1 P31749 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ ASIC3 Q9UHC3 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ AOC3 Q16853 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2427481 0.88 ADRB2 (1.00) ADRB2HRH3TAAR1LOXL2CYP2A6
SCHEMBL28135249 0.86 ADRB2 (0.96) ADRB2HRH3TAAR1LOXL2CYP2A6
SCHEMBL31565171 0.82 ADRB2 (0.62) ADRB2HRH3TAAR1LOXL2CYP2A6
SCHEMBL18814003 0.82 ADRB2 (0.62) ADRB2HRH3TAAR1LOXL2CYP2A6
SCHEMBL19010904 0.81 ADRB2 (0.50) ADRB2NPC1MAPK1RAB9ACLK4
SCHEMBL13978027 0.78 RAB9A (0.48) ADRB2TAAR1NPC1MAPK1RAB9A
SCHEMBL16269874 0.77 ADRB2 (0.66) ADRB2HRH3TAAR1LOXL2CYP2A6
SCHEMBL13977594 0.76 ADRB2 (0.53) ADRB2HRH3TAAR1LOXL2CYP2A6
SCHEMBL22112582 0.74 NPC1 (0.70) ADRB2CYP2A6NPC1MAPK1RAB9A
Hydrochloric Acid SCHEMBL16915167 0.74 ADRB2 (0.52) ADRB2HRH3TAAR1LOXL2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025094139-A1 SIMULTANEOUS DETECTION OF MULTIPLE ALZHEIMER BIOMARKERS MARA NANOTECH, INC. (KR) 2025-05-08 — — WO disclosed
WO-2023201008-A1 COMPOSITIONS AND METHODS FOR LOCALIZED DELIVERY OF CYTOKINES FOR ADOPTIVE CELL THERAPY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-10-19 — — WO disclosed
US-11771767-B2 Reduced and oxidized polysaccharides and methods of use thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-10-03 — — US disclosed
US-11771767-B2 Reduced and oxidized polysaccharides and methods of use thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-10-03 — — US disclosed
EP-4245744-A2 CHEMICALLY CLEAVABLE GROUP Tagworks Pharmaceuticals B.V. (NL) 2023-09-20 — — EP disclosed
EP-2922574-B1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B V (NL) 2023-05-17 — — EP disclosed
US-20210284776-A1 COMPOSITIONS AND METHODS FOR LABELING AND MODULATION OF CELLS IN VITRO AND IN VIVO PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-09-16 — — US disclosed
WO-2021155297-A1 METHODS FOR LABELING AND TARGETING CELLS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-08-05 — — WO disclosed
EP-3821880-A1 OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF President and Fellows of Harvard College (US) 2021-05-19 — — EP disclosed
US-20210128790-A1 CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-05-06 — — US disclosed
US-20160151505-A1 BIO-ORTHOGONAL DRUG ACTIVATION KONINKLIJKE PHILIPS N.V. (NL) 2016-06-02 — — US disclosed
US-20150344514-A1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-12-03 — — US disclosed
US-20150344514-A1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-12-03 — — US disclosed
US-20150297741-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-10-22 — — US disclosed
US-20150297741-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-10-22 — — US disclosed
WO-2014081299-A1 ACTIVATABLE LIPOSOMES TAGWORKS PHARMACEUTICALS B.V. (NL) 2014-05-30 — — WO disclosed
WO-2014081300-A1 CHANNEL PROTEIN ACTIVATABLE LIPOSOMES TAGWORKS PHARMACEUTICALS B.V. (NL) 2014-05-30 — — WO disclosed
WO-2014081303-A1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B.V. (NL) 2014-05-30 — — WO disclosed
WO-2014081301-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2014-05-30 — — WO disclosed
WO-2012156920-A1 BIO-ORTHOGONAL DRUG ACTIVATION KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) 2012-11-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128790-A1 CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE VCL, CD44, LOX ADRB2 4700/4885HRH3 3880/4885TAAR1 4034/4885
US-20150344514-A1 CHEMICALLY CLEAVABLE GROUP SQLE, CTRL, ENO1 ADRB2 2324/4885HRH3 1402/4885TAAR1 1064/4885
US-11771767-B2 Reduced and oxidized polysaccharides and methods of use thereof ALG1, LPO, FUT5 ADRB2 4225/4885HRH3 4359/4885TAAR1 4329/4885
US-20210284776-A1 COMPOSITIONS AND METHODS FOR LABELING AND MODULATION OF CELLS IN VITRO AND IN VIVO CD47, LY6K, CD68 ADRB2 4632/4885HRH3 3576/4885TAAR1 3077/4885
US-20150297741-A1 BIO-ORTHOGONAL DRUG ACTIVATION KIT, JMJD7, TPSB2 ADRB2 690/4885HRH3 700/4885TAAR1 2555/4885
US-20160151505-A1 BIO-ORTHOGONAL DRUG ACTIVATION JMJD7, KIT, PAICS ADRB2 2300/4885HRH3 1108/4885TAAR1 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.